Targeting CTA and/or TAA using vaccination strategies has been suggested because of their frequent expression in a large proportion of HCC cells (i.e.: MAGE-A1 and A3: > 50%; NY-ESO-1 > 30%, and SSX2 > 70%) [11, 17, 18]. This evidence concerns the gene MAGEA1 and hepatocellular carcinoma.